Interim results for the six months ended June 30, 2026
September 11, 2026Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Interim results for the six months ended June 30, 2026Biodexa Pharmaceuticals PLC NASDAQ:BDRX, a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestina…